Skip to main content
Top
Published in: International Urology and Nephrology 5/2013

01-10-2013 | Urology - Original Paper

Predictors of Gleason score upgrading in a large African-American population

Authors: Anup Vora, Tim Large, Jenny Aronica, Sherod Haynes, Andrew Harbin, Daniel Marchalik, Hanaa Nissim, John Lynch, Gaurav Bandi, Kevin McGeagh, Keith Kowalczyk, Reza Ghasemian, Krishnan Venkatesan, Mohan Verghese, Jonathan Hwang

Published in: International Urology and Nephrology | Issue 5/2013

Login to get access

Abstract

Purpose

Gleason score from biopsy specimens is important for prostate cancer (PCa) risk stratification and influences treatment decisions. Gleason score upgrading (GSU) between biopsy and surgical pathology specimens has been reported as high as 50 % and presents a challenge in counseling low-risk patients. While recent studies have investigated predictors of GSU, populations in these studies have been largely Caucasian. We report our analysis of predictors of GSU in a large urban African-American population.

Methods

A total of 959 patients with D’Amico low-risk prostate cancer underwent radical prostatectomy at Georgetown University or Washington Hospital Center between January 2005 and July 2012. Race, age, PSA, body mass index (BMI), cancer of the prostate risk assessment (CAPRA) score, and transrectal ultrasound (TRUS) biopsy characteristics (percent of biopsy cores showing adenocarcinoma, highest percent of biopsy core involved with cancer, and measured TRUS prostate volume) were analyzed with both univariate and multivariate analyses to identify significant predictors of GSU while controlling for clinical parameters.

Results

Of the 959 cases, 288 (30.0 %) were upgraded on final pathologic specimen with approximately 38 % (133/355) of African-American patients experiencing GSU. BMI (P = 0.02), percent positive biopsy cores (P < 0.01) and percent of core involved with cancer (P < 0.01), increasing CAPRA score, and serum PSA were independent predictors of GSU on both uni- and multivariate regression analyses. African Americans had a 73 % increase in the incidence of GSU over other races.

Conclusion

More than a quarter of low-risk prostate cancer patients were upgraded on final pathology in our series. Higher BMI, serum PSA, CAPRA score, percent of cores positive, and percent of cores involved were independent predictors of GSU. Individuals with those clinical parameters may harbor occult high-grade disease and should be carefully counseled on treatment decisions.
Literature
2.
go back to reference Turley RS, Terris MK, Kane CJ, Aronson WJ, Presti JC Jr, Amling CL, Freedland SJ (2008) The association between prostate size and Gleason score upgrading depends on the number of biopsy cores obtained: results from the shared equal access regional cancer hospital database. BJU Int 102(9):1074–1079PubMedCrossRef Turley RS, Terris MK, Kane CJ, Aronson WJ, Presti JC Jr, Amling CL, Freedland SJ (2008) The association between prostate size and Gleason score upgrading depends on the number of biopsy cores obtained: results from the shared equal access regional cancer hospital database. BJU Int 102(9):1074–1079PubMedCrossRef
3.
go back to reference D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969–974PubMedCrossRef D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969–974PubMedCrossRef
4.
go back to reference Fu Q, Moul JW, Bañez LL, Sun L, Mouraviev V, Xie D, Polascik TJ (2008) Association between percentage of tumor involvement and Gleason score upgrading in low-risk prostate cancer. Med Oncol 29(5):3339–3344CrossRef Fu Q, Moul JW, Bañez LL, Sun L, Mouraviev V, Xie D, Polascik TJ (2008) Association between percentage of tumor involvement and Gleason score upgrading in low-risk prostate cancer. Med Oncol 29(5):3339–3344CrossRef
5.
go back to reference Oh JJ, Hong SK, Lee JK, Lee BK, Lee S, Kwon OS, Byun SS, Lee SE (2012) Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy. BJU Int 110(11 Pt B):E494–E499PubMedCrossRef Oh JJ, Hong SK, Lee JK, Lee BK, Lee S, Kwon OS, Byun SS, Lee SE (2012) Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy. BJU Int 110(11 Pt B):E494–E499PubMedCrossRef
6.
go back to reference Gleason DF, Mellinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111(1):58–64PubMed Gleason DF, Mellinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111(1):58–64PubMed
7.
go back to reference Cohen MS, Hanley RS, Kurteva T, Ruthazer R, Silverman ML, Sorcini A, Hamawy K, Roth RA, Tuerk I, Libertino JA (2008) Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey clinic medical center experience and an international meta-analysis. Eur Urol 54(2):371–381PubMedCrossRef Cohen MS, Hanley RS, Kurteva T, Ruthazer R, Silverman ML, Sorcini A, Hamawy K, Roth RA, Tuerk I, Libertino JA (2008) Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey clinic medical center experience and an international meta-analysis. Eur Urol 54(2):371–381PubMedCrossRef
8.
go back to reference Cookson MS, Fleshner NE, Soloway SM, Fair WR (1997) Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol 157(2):559–562PubMedCrossRef Cookson MS, Fleshner NE, Soloway SM, Fair WR (1997) Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol 157(2):559–562PubMedCrossRef
9.
go back to reference Cecchi M, Minervini R, Sepich CA, Ippolito C, Pagni GL, Summonti D, Di Benedetto A, Fiorentini L (1998) Correlation between Gleason score of needle biopsy and radical prostatectomy tissue. Int Urol Nephrol 30(5):575–580PubMedCrossRef Cecchi M, Minervini R, Sepich CA, Ippolito C, Pagni GL, Summonti D, Di Benedetto A, Fiorentini L (1998) Correlation between Gleason score of needle biopsy and radical prostatectomy tissue. Int Urol Nephrol 30(5):575–580PubMedCrossRef
10.
go back to reference Fernandes ET, Sundaram CP, Long R, Soltani M, Ercole CJ (1997) Biopsy Gleason score: how does it correlate with the final pathological diagnosis in prostate cancer? Br J Urol 79(4):615–617PubMedCrossRef Fernandes ET, Sundaram CP, Long R, Soltani M, Ercole CJ (1997) Biopsy Gleason score: how does it correlate with the final pathological diagnosis in prostate cancer? Br J Urol 79(4):615–617PubMedCrossRef
11.
go back to reference Davies JD, Aghazadeh MA, Phillips S, Salem S, Chang SS, Clark PE, Cookson MS, Davis R, Herrell SD, Penson DF, Smith JA Jr, Barocas DA (2011) Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer. J Urol 186(6):2221–2227PubMedCrossRef Davies JD, Aghazadeh MA, Phillips S, Salem S, Chang SS, Clark PE, Cookson MS, Davis R, Herrell SD, Penson DF, Smith JA Jr, Barocas DA (2011) Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer. J Urol 186(6):2221–2227PubMedCrossRef
12.
go back to reference Turley RS, Hamilton RJ, Terris MK, Kane CJ, Aronson WJ, Presti JC Jr, Amling CL, Freedland SJ (2008) Small transrectal ultrasound volume predicts clinically significant Gleason score upgrading after radical prostatectomy: results from the SEARCH database. J Urol 179(2):523–527PubMedCrossRef Turley RS, Hamilton RJ, Terris MK, Kane CJ, Aronson WJ, Presti JC Jr, Amling CL, Freedland SJ (2008) Small transrectal ultrasound volume predicts clinically significant Gleason score upgrading after radical prostatectomy: results from the SEARCH database. J Urol 179(2):523–527PubMedCrossRef
13.
go back to reference Thomas C, Pfirrmann K, Pieles F, Bogumil A, Gillitzer R, Wiesner C, Thüroff JW, Melchior SW (2012) Predictors for clinically relevant Gleason score upgrade in patients undergoing radical prostatectomy. BJU Int 109(2):214–219PubMedCrossRef Thomas C, Pfirrmann K, Pieles F, Bogumil A, Gillitzer R, Wiesner C, Thüroff JW, Melchior SW (2012) Predictors for clinically relevant Gleason score upgrade in patients undergoing radical prostatectomy. BJU Int 109(2):214–219PubMedCrossRef
14.
go back to reference Corcoran NM, Casey RG, Hong MK, Pedersen J, Connolly S, Peters J, Harewood L, Gleave ME, Costello AJ, Hovens CM, Goldenberg SL (2012) The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume. BJU Int 110(1):36–42PubMedCrossRef Corcoran NM, Casey RG, Hong MK, Pedersen J, Connolly S, Peters J, Harewood L, Gleave ME, Costello AJ, Hovens CM, Goldenberg SL (2012) The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume. BJU Int 110(1):36–42PubMedCrossRef
15.
go back to reference Tilki D, Schlenker B, John M, Buchner A, Stanislaus P, Gratzke C, Karl A, Tan GY, Ergün S, Tewari AK, Stief CG, Seitz M, Reich O (2011) Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series. Urol Oncol 29(5):508–514PubMedCrossRef Tilki D, Schlenker B, John M, Buchner A, Stanislaus P, Gratzke C, Karl A, Tan GY, Ergün S, Tewari AK, Stief CG, Seitz M, Reich O (2011) Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series. Urol Oncol 29(5):508–514PubMedCrossRef
16.
go back to reference Epstein JI, Feng Z, Trock BJ, Pierorazio PM (2012) Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 61(5):1019–1024PubMedCrossRef Epstein JI, Feng Z, Trock BJ, Pierorazio PM (2012) Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 61(5):1019–1024PubMedCrossRef
17.
go back to reference Gershman B, Dahl DM, Olumi AF, Young RH, Scott McDougal W, Wu CL (2011) Smaller prostate gland size and older age predict Gleason score upgrading. Urol Oncol (epub) Gershman B, Dahl DM, Olumi AF, Young RH, Scott McDougal W, Wu CL (2011) Smaller prostate gland size and older age predict Gleason score upgrading. Urol Oncol (epub)
19.
go back to reference Powell IJ (2011) The precise role of ethnicity and family history on aggressive prostate cancer: a review analysis. Arch Esp Urol 64(8):711–719PubMed Powell IJ (2011) The precise role of ethnicity and family history on aggressive prostate cancer: a review analysis. Arch Esp Urol 64(8):711–719PubMed
20.
go back to reference Powell IJ, Bock CH, Ruterbusch JJ, Sakr W (2010) Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol 183(5):1792–1796PubMedCrossRef Powell IJ, Bock CH, Ruterbusch JJ, Sakr W (2010) Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol 183(5):1792–1796PubMedCrossRef
21.
go back to reference Bigler SA, Pound CR, Zhou X (2011) A retrospective study on pathologic features and racial disparities in prostate cancer. Prostate Cancer 239460:101–108 Bigler SA, Pound CR, Zhou X (2011) A retrospective study on pathologic features and racial disparities in prostate cancer. Prostate Cancer 239460:101–108
22.
go back to reference Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, Carroll PR (2005) The University of California, San Francisco cancer of the prostate risk assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 173(6):1938–1942PubMedCrossRef Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, Carroll PR (2005) The University of California, San Francisco cancer of the prostate risk assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 173(6):1938–1942PubMedCrossRef
23.
go back to reference Meurs P, Galvin R, Fanning DM, Fahey T (2012) Prognostic value of the CAPRA clinical prediction rule: a systematic review and meta-analysis. BJU Int 111(3):427–436PubMedCrossRef Meurs P, Galvin R, Fanning DM, Fahey T (2012) Prognostic value of the CAPRA clinical prediction rule: a systematic review and meta-analysis. BJU Int 111(3):427–436PubMedCrossRef
Metadata
Title
Predictors of Gleason score upgrading in a large African-American population
Authors
Anup Vora
Tim Large
Jenny Aronica
Sherod Haynes
Andrew Harbin
Daniel Marchalik
Hanaa Nissim
John Lynch
Gaurav Bandi
Kevin McGeagh
Keith Kowalczyk
Reza Ghasemian
Krishnan Venkatesan
Mohan Verghese
Jonathan Hwang
Publication date
01-10-2013
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 5/2013
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-013-0495-y

Other articles of this Issue 5/2013

International Urology and Nephrology 5/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine